[Federal Register Volume 75, Number 56 (Wednesday, March 24, 2010)]
[Notices]
[Pages 14189-14190]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-6420]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on January 14, 2010, Siegfried 
(USA), 33 Industrial Park Road, Pennsville, New Jersey 08070, made 
application by renewal to the Drug Enforcement Administration (DEA) as 
a bulk manufacturer of the basic classes of controlled substances in 
schedules I and II:

[[Page 14190]]



------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Dihydromorphine (9145).....................   I
Amphetamine (1100).........................  II
Methylphenidate (1724).....................   II
Amobarbital (2125).........................  II
Pentobarbital (2270).......................   II
Secobarbital (2315)........................  II
Glutethimide (2550)........................   II
Codeine (9050).............................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................   II
Hydrocodone (9193).........................   II
Methadone (9250)...........................   II
Methadone intermediate (9254)..............   II
Dextropropoxyphene, bulk (non-dosage forms)   II
 (9273).
Morphine (9300)............................   II
Oripavine (9330)...........................   II
Oxymorphone (9652).........................   II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, VA 22152; and must be filed no later 
than May 24, 2010.

    Dated: March 16, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2010-6420 Filed 3-23-10; 8:45 am]
BILLING CODE 4410-09-P